Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

8.125 +0.035 (+0.43%)
Streaming Delayed Price Updated: 1:53 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Agenus to Participate in Upcoming September Investor Conferences
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
From Agenus Inc.
Via Business Wire
Agenus (NASDAQ:AGEN) Passes Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
From Agenus Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Sphere 3D (NASDAQ: ANY) Engages Specialized Government Affairs Firms, Expands AI Infrastructure Strategy Across Tennessee Valley Authority Region
Via AB Newswire
Topics Artificial Intelligence
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Discover the most active stocks in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk... 
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗
Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while... 
Via MarketBeat
News headline image
Agenus Announces Virtual 2026 Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
News headline image
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
From Agenus Inc. & BAP Pharma
Via Business Wire
News headline image
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.